Bullish Case: Unity Biotechnology has developed UBX1325, a drug candidate in a phase II clinical trial for age-related eye diseases [stockinvest.us, wallstreetzen.com]. Encouraging data from previous trials and analysts' positive price target indicate potential upside [benzinga.com, Yahoo].


Bearish Case: Continued downward price movement and dwindling market capitalization hint at investor skepticism [Helium, Helium, Helium]. Additionally, lack of current revenue generation [marketbeat.com, marketbeat.com] and low market volatility may signal reduced investor interest [Helium, Helium].


Takeaway: Currently, Unity Biotechnology appears relatively risky due to dwindling stock prices and lack of revenue generation. However, success of its drug UBX1325 in ongoing trials could unlock significant value.


Potential Outcomes:

1. UBX1325 passes phase II clinical trial - 65%; Potential breakthrough in treatment for age-related diseases can lead to a surge in stock price [stockinvest.us].

2. UBX1325 fails phase II clinical trial - 25%; Potential failure could significantly dampen investor sentiment leading to further stock devaluation.

3. Change in market perception or analyst predictions - 10%; Sudden shifts in investor sentiment or analyst revisions can lead to upward or downward price adjustments [benzinga.com].


September 07, 2023


Unity Biotechnology Forecast

[UBX]  Unity Biotechnology
Price Forecast: NEUTRAL    Price Action: FLAT




Access longer forecasts + daily optimized trades.


Correlated Stock Forecasts

Assets that tend to move strongly with UBX



NVCR Forecast + Options Trading Strategies   [NVCR]  NovoCure (0.53)


GRWG Forecast + Options Trading Strategies   [GRWG]  GrowGeneration (0.47)


DCGO Forecast + Options Trading Strategies   [DCGO]  DocGo (0.47)


CHWY Forecast + Options Trading Strategies   [CHWY]  Chewy (0.47)


GERN Forecast + Options Trading Strategies   [GERN]  Geron (0.47)



Uncorrelated Stock Forecasts

Assets with little price relationship to UBX



HSBC Forecast + Options Trading Strategies   [HSBC]  HSBC (0.0)


ASML Forecast + Options Trading Strategies   [ASML]  New York Shares (0.0)


OPEN Forecast + Options Trading Strategies   [OPEN]  Opendoor (0.0)


LVS Forecast + Options Trading Strategies   [LVS]  Las Vegas Sands (-0.01)


NXPI Forecast + Options Trading Strategies   [NXPI]  NXP Semiconductors (-0.01)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against UBX



ONON Forecast + Options Trading Strategies   [ONON]  On (-0.33)


CNK Forecast + Options Trading Strategies   [CNK]  Cinemark (-0.37)


IONQ Forecast + Options Trading Strategies   [IONQ]  IonQ (-0.38)


CBOE Forecast + Options Trading Strategies   [CBOE]  Cboe Global Markets (-0.5)


PG Forecast + Options Trading Strategies   [PG]  Procter & Gamble (-0.55)